Sponsor Pipeline

Peng Zhang Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
3
Active Trials
3
Recruiting
2
Disease Areas
What Changed in the Last 30 Days
First PostedNew Trial FilingPhaseStatus
2026-08-03 NCT07742332 Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC Phase 2 Recruiting
Active Trials by Phase
Phase 2
2
Early Phase 1
1
Active Trials
NCT IDTitleConditionStatus
Phase 2
NCT06755684 Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for… EGFR Recruiting
NCT07742332 Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC EGFR Recruiting
Early Phase 1
NCT06119490 Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK… Toxic Epidermal Necrolysis Recruiting
Disease Areas
Non-Small Cell Lung Cancer (NSCLC) (2) Lung Cancer (2)
Get alerts when Peng Zhang's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free